A phase I/II, open-label study of the safety, tolerance, pharmacokinetics, drug-interaction and anti-HIV activity of intramuscularly administered alpha-epi-Br (HE2000) in HIV-infected patients on salvage therapy.
Phase of Trial: Phase I/II
Latest Information Update: 24 Jun 2012
At a glance
- Drugs HE 2000 (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 30 Jun 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2005 New trial record.